Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1386 in Healthy Caucasian Young and Elderly Subjects After Oral Multiple Doses.

NCT00690079 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00690079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00690079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1386 in Healthy Caucasian Young and Elderly Subjects After Oral Multiple Doses.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2008
Completion date
October 31, 2008
Enrollment
69 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic pain